FIELD: biotechnology.
SUBSTANCE: invention relates to peptides which can reactivate effectively and specifically p53 mutants. In particular, peptides which reactivate mutant p53, which can restore native folding of wild-type p53 and therefore tumour suppressor activity with respect to p53 mutant protein are disclosed.
EFFECT: such peptides can be suitable for treating various conditions and diseases, in which p53 protein is mutated.
11 cl, 21 dwg, 10 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDES AND THEIR USE IN TREATMENT OF DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH MUTANT p53 | 2017 |
|
RU2762089C2 |
| MODIFIED MITOCHONDRIA AND THEIR USE | 2019 |
|
RU2811467C2 |
| NEOANTIGENS AND THEIR APPLICATION | 2019 |
|
RU2805196C2 |
| ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND TREATMENT | 2020 |
|
RU2806915C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| ANTIBODIES SPECIFIC FOR CD70 AND THEIR USE | 2019 |
|
RU2801093C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
